Co-administration of an HER2-specific mAb with an HER2-targeted tumor vaccine enhanced the induction of HER2/neu-specific CD8-positive T cells through Fc-mediated dendritic cell activation [27]. The gene discussed is CD8A; the disease is neoplasm.